- Policy
- Domestic DM combi drugs selected for market competitiveness
- by Lee, Tak-Sun May 23, 2023 05:50am
- LG Chem and Dong-A ST are attracting attention by listing their DPP4i+SGLT2i combination as benefits, lowering the amount added. It is interpreted as being conscious of price competitiveness. According to the industry on the 22nd, Dong-A ST Sugadapa set the upper limit lower than the formula based on addition. This drug is an improved new
- Company
- SGLT2 lowers BP, but more evidence is needed to use it alone
- by Hwang, Jin-joon May 23, 2023 05:50am
- There was an opinion that there is still insufficient evidence for the use of the sodium-glucose cotransporter-2 (SGLT-2) inhibitor, a treatment for type 2 diabetes and heart failure, for the treatment of hypertension. It can be expected to lower blood pressure in patients with heart failure or diabetes, but it is difficult to use it alone f
- Company
- AZ runs a neurofibromatosis disease awareness campaign
- by Jung, Sae-Im May 22, 2023 05:42am
- AstraZeneca Korea announced on the 18th that it had conducted the 'Twinkling a Light for NF-1 Campaign' for its executives and employees to support domestic neurofibromatosis patients in celebration of 'World Neurofibromatosis Awareness Day'. The Children's Cancer Foundation designated May 17 every year as World Neurofibromatosis Awareness Day t
- Company
- Hana Pharm, signed a sub-license agreement for Byfav
- by Lee, Seok-Jun May 22, 2023 05:42am
- Hana Pharm announced on the 18th that it had signed a sub-license contract with Hyphens Pharma of Singapore for the exclusive rights to Byfavo 20mg, an anesthetic new drug. This contract is the first achievement of local partnering while Hana Pharm received licenses for six Southeast Asian countries from German PiON in 2020 and was in the pro
- Policy
- Myelofibrosis tx BMS Inrebic to be covered from June
- by Lee, Tak-Sun May 22, 2023 05:42am
- BMS Korea's myelofibrosis drug Inrebic will be covered from June. This drug is expected as a second-line treatment option for myelofibrosis patients, of which there are about 1,700 in Korea. According to the industry on the 19th, Inrebic will be listed as a salary at 39,520 won per capsule for the maximum amount from June 1st. Inrevic Caps
- Company
- New formulations for schizophrenia are being commercialized
- by Eo, Yun-Ho May 22, 2023 05:42am
- According to related industries, new long-acting formulations of existing schizophrenia treatment drugs, such as Abilify and Invega, are being released one after another. Lundbeck and Otsuka Pharmaceutical obtained US FDA approval for Abilify Asimtufii, which is administered once every two months, last month. Abilify Asimtufii confirmed i
- Company
- “Need to increase support for new AI drugs in Korea”
- by Jung, Sae-Im May 22, 2023 05:42am
- “Although artificial intelligence (AI) new drug development ecosystem is being created in Korea, there are still many areas that we are lacking at a global level in terms of manpower or investment scale. Chinese companies that were established around the same time received more than KRW 500 billion in investments, while Korean companies only re
- Policy
- Vemlidy’s price 4.7% ↓...Vemliver’s voluntarily 12.6% ↓
- by Kim, Jung-Ju May 22, 2023 05:42am
- Gilead’s adult chronic hepatitis B treatment, ‘Vemlidi Tab (tenofovir ala fenamide) will be subject to Price-Volume Agreement price cuts and be sold at a 4.7% lower price starting next month. Daewoong Pharmaceutical opted to reduce the price of its latecomer Vemliver Tab by 12.6%. According to industry sources on the 21st, the Ministry
- Company
- Attempts to develop new drugs for hypertension
- by Hwang, Jin-joon May 22, 2023 05:41am
- Opinions were raised that it would be difficult for candidates under development as new drugs for hypertension, such as Baxdrostat, Aprocitentan, and Firibastat, to replace existing drugs. It is expected that it will fill the unmet demand rather than take the place of the prescribed treatment. Professor Woong-Gil Choi of Chungbuk National
- Company
- Forxiga price cut enforcement suspension extended
- by Jung, Sae-Im May 19, 2023 05:48am
- A decision on whether to suspend the execution of drug price cuts for AstraZeneca Korea’s diabetes treatments Forxiga and Xigduo is expected to be decided at the end of this month at the earliest. The temporary suspension period, originally until May 19, is also extended. On the 16th, the first division of the Seoul Administrative Court held an
